• Mirum Pharmaceuticals reported topline Phase 3 EXPAND results for LIVMARLI in ultra-rare cholestatic liver diseases, including biliary atresia.
• The trial met its primary endpoint, showing a clear improvement in cholestatic itch versus placebo.
• Secondary measures also favored LIVMARLI, including results in biliary atresia patients with a native liver.
• Safety was consistent with prior experience, with no new safety signals reported.
• A U.S. supplemental NDA filing is planned for the first half of 2027; results will be discussed on an investor call today.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261012685221) on October 12, 2026, and is solely responsible for the information contained therein.